PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15590399-6	2004	Fludarabine was administered intravenously at 25 mg/m2/day for 5 days once every 6 weeks with IFN in weeks 4 and 5 at 3x10(6) U/m2 subcutaneously three times weekly for 6 doses.	fludarabine	0-11	interferon alpha 1	Homo sapiens	94-97	
7632936-4	1995	We used recombinant alpha interferon (IFN-alpha) maintenance therapy in patients with CLL who achieved remission in response to fludarabine therapy to determine its effect on residual disease, assessed by either bone marrow biopsy or flow cytometry, and on immune restoration.	fludarabine	128-139	interferon alpha 1	Homo sapiens	38-47	
14687987-1	2003	BACKGROUND AND OBJECTIVES: Fludarabine is an effective therapy for patients with chronic lymphocytic leukemia (CLL) and interferon-alpha (IFN-alpha) has been reported to have anti-leukemic activity in CLL patients.	fludarabine	27-38	interferon alpha 1	Homo sapiens	138-147	
14687987-2	2003	A randomized study was designed to evaluate whether the addition of IFN-alpha to a first-line treatment with fludarabine and prednisone could increase the response rate in patients with advanced CLL and whether IFN-alpha given as maintenance therapy could improve the duration of response.	fludarabine	109-120	interferon alpha 1	Homo sapiens	68-77	
7931473-10	1994	CONCLUSION: The combination of fludarabine with continuous low-dose IFN is an active regimen in patients with advanced MF/SS, including patients with visceral involvement and patients who progressed after prior therapy with DCF and IFN.	fludarabine	31-42	interferon alpha 1	Homo sapiens	232-235	
22479354-8	2012	IFN-alpha stimulation of GLS1 promoter activity correlated to STAT1 phosphorylation and was reduced by fludarabine, a chemical that inhibits STAT1 phosphorylation.	fludarabine	103-114	interferon alpha 1	Homo sapiens	0-9